TY - JOUR
T1 - Apparent ELISA detection times for albuterol after administration with the Torpex equine inhaler device
AU - Dirikolu, Levent
AU - Mollett, Brad
AU - Troppmann, Amy
AU - Woods, William
AU - Bratton, Calvert
AU - Cashman, Conor
AU - Schroedter, Dwight
AU - Mayer, Brent
AU - Lehner, Andreas
AU - Karpiesiuk, Wojciech
AU - Hughes, Charlie
AU - Boyles, Jeff
AU - Harkins, John
AU - Tobin, Thomas
AU - Rosenthal, Marie
PY - 2002
Y1 - 2002
N2 - Single doses of one, three, and six actuations (120 μg albuterol/actuation) and multiple daily doses (six actuations per dose four times daily) for 5 days of aerosol albuterol sulfate were sequentially administered to each of six horses using an equine inhaler device (3M Animal Care Products, St. Paul, MN and Boehringer Ingleheim Vetmedica, Inc., St. Joseph, MO.). A 2-week washout period was allowed between each dose. ELISA testing revealed no evidence of albuterol in urine at 24 hours after any single-dose administration. Results indicated that 48 hours or longer should be allowed for albuterol to be cleared from urine after single doses. When given at the maximum recommended rate of six actuations per dose four times a day for 5 days, urine samples tested by ELISA showed no evidence of albuterol at 48 hours after the final dose. Testing of nasal swabs by ELISA demonstrated the presence of albuterol for 8 hours after each single dose, and some horses might have detectable levels of albuterol in nasal swabs for several days following administration of multiple doses. As a guideline for withdrawal time, 72 hours or longer should be allowed after administration of aerosol albuterol sulfate to horses before participation in equestrian competitions that are regulated for detection of certain performance-enhancing substances. However, these recommendations were based on a small sample of horses and the specific ELISA test used and interpreted as described. Factors specific to individual horses may influence these detection times.
AB - Single doses of one, three, and six actuations (120 μg albuterol/actuation) and multiple daily doses (six actuations per dose four times daily) for 5 days of aerosol albuterol sulfate were sequentially administered to each of six horses using an equine inhaler device (3M Animal Care Products, St. Paul, MN and Boehringer Ingleheim Vetmedica, Inc., St. Joseph, MO.). A 2-week washout period was allowed between each dose. ELISA testing revealed no evidence of albuterol in urine at 24 hours after any single-dose administration. Results indicated that 48 hours or longer should be allowed for albuterol to be cleared from urine after single doses. When given at the maximum recommended rate of six actuations per dose four times a day for 5 days, urine samples tested by ELISA showed no evidence of albuterol at 48 hours after the final dose. Testing of nasal swabs by ELISA demonstrated the presence of albuterol for 8 hours after each single dose, and some horses might have detectable levels of albuterol in nasal swabs for several days following administration of multiple doses. As a guideline for withdrawal time, 72 hours or longer should be allowed after administration of aerosol albuterol sulfate to horses before participation in equestrian competitions that are regulated for detection of certain performance-enhancing substances. However, these recommendations were based on a small sample of horses and the specific ELISA test used and interpreted as described. Factors specific to individual horses may influence these detection times.
UR - http://www.scopus.com/inward/record.url?scp=79251521522&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79251521522&partnerID=8YFLogxK
M3 - Article
C2 - 12447838
AN - SCOPUS:79251521522
SN - 1528-3593
VL - 3
JO - Veterinary Therapeutics
JF - Veterinary Therapeutics
IS - 3
ER -